Sanjivani Paranteral Ltd
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]
- Market Cap ₹ 206 Cr.
- Current Price ₹ 168
- High / Low ₹ 269 / 132
- Stock P/E 24.7
- Book Value ₹ 36.5
- Dividend Yield 0.30 %
- ROCE 28.5 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 31.3%
- Debtor days have increased from 59.2 to 86.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 54.41 | 70.10 | 73.63 | |
| 46.18 | 59.76 | 62.29 | |
| Operating Profit | 8.23 | 10.34 | 11.34 |
| OPM % | 15.13% | 14.75% | 15.40% |
| 0.52 | 1.22 | 0.93 | |
| Interest | 0.25 | 0.59 | 0.68 |
| Depreciation | 0.93 | 0.62 | 0.74 |
| Profit before tax | 7.57 | 10.35 | 10.85 |
| Tax % | 18.63% | 21.84% | |
| 6.17 | 8.09 | 8.34 | |
| EPS in Rs | 5.28 | 6.81 | 6.87 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 71% |
| 3 Years: | 47% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 11.68 | 11.88 | 12.28 |
| Reserves | 16.22 | 26.11 | 32.55 |
| 0.97 | 8.14 | 9.30 | |
| 14.53 | 32.07 | 18.90 | |
| Total Liabilities | 43.40 | 78.20 | 73.03 |
| 9.94 | 20.64 | 21.36 | |
| CWIP | 0.00 | 19.11 | 24.09 |
| Investments | 0.00 | 0.00 | 0.00 |
| 33.46 | 38.45 | 27.58 | |
| Total Assets | 43.40 | 78.20 | 73.03 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -10.70 | 12.40 | |
| -12.21 | -21.91 | |
| 23.16 | 10.46 | |
| Net Cash Flow | 0.24 | 0.94 |
| Free Cash Flow | -14.00 | -17.95 |
| CFO/OP | -117% | 133% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 31.53 | 86.85 |
| Inventory Days | 124.70 | 94.77 |
| Days Payable | 73.56 | 137.51 |
| Cash Conversion Cycle | 82.67 | 44.11 |
| Working Capital Days | 35.55 | -0.10 |
| ROCE % | 28.46% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Inventory Levels INR Crores ・Standalone data |
|
|||||||
| Export Revenue Mix % ・Standalone data |
||||||||
| Number of Countries in Reach number ・Standalone data |
||||||||
| Product Portfolio Size number ・Standalone data |
||||||||
| Annual Ampoules Capacity million |
||||||||
| Annual B Lactam Tablet Capacity million |
||||||||
| Annual Liquid Injectables Capacity million |
||||||||
| Annual Tablet Capacity (General) million |
||||||||
| Annual Vial Capacity million |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Certificate under Reg 74(5) of SEBI (DP) Reg 2018 for the Quarter and Year ended on 31.03.2026.
-
Disclosure Under Regulation 31(4) Of The Securities Exchange Board Of India (Substantial Acquisition Of Shares And Takeovers) Regulation, 2011
2 Apr - Annual disclosure under Regulation 31(4) for FY ended 31 March 2026 submitted by promoter.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1 Apr
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Mar
-
Closure of Trading Window
28 Mar - Trading window closed from 01-Apr-2026 until 48 hours after audited FY2026 results public.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
SPL is a WHO-GMP, DIGEMID, and DDA-certified pharmaceutical company specializing in high-quality parenteral and oral solid formulations. It serves key therapeutic areas including CNS, CVS, antibiotics, urology, anesthetics, gastroenterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants, and vitamin supplements.